Mericitabine (RG-7128) is an antiviral drug, a deoxycytidine analog (a type of nucleoside analog). It was developed as a treatment for hepatitis C, acting as a NS5B RNA polymerase inhibitor, but while it showed a good safety profile in clinical trials, it was not sufficiently effective to be used as a stand-alone agent. However mericitabine has been shown to boost the efficacy of other antiviral drugs when used alongside them, and as most modern treatment regimens for hepatitis C use a combination therapy of several antiviral drugs, clinical trials have continued to see if it can form a part of a clinically useful drug treatment program.[1][2]
Clinical data | |
---|---|
Trade names | Mericitabine |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
KEGG |
|
Chemical and physical data | |
Formula | C18H26FN3O6 |
Molar mass | 399.419 g·mol−1 |
3D model (JSmol) |
|
| |
|